Association Between Gastroesophageal Reflux Disease and Hypertension: A Systematic Review and Meta‐Analysis

JGH Open, Journal Year: 2025, Volume and Issue: 9(4)

Published: April 1, 2025

Gastroesophageal reflux disease (GERD) and hypertension (HTN) are common conditions with substantial health burdens. While prior studies suggest a link between GERD HTN, findings remain inconsistent. This systematic review meta-analysis aimed to clarify the relationship HTN. A search of PubMed, Web Science, Embase was conducted identify observational published through December 2024. Studies evaluating prevalence association HTN were included. Screening data extraction performed using Nested Knowledge software, quality assessed via Modified Newcastle-Ottawa Scale. Random-effects meta-analyses used calculate pooled risk estimates, while heterogeneity quantified I 2 statistic. Publication bias evaluated DOI funnel plots. Twelve studies, sample sizes ranging from 71 12 960 participants, The among patients 16.80% (95% CI: 6.28%-31.02%) high (I = 99%). ratio (RR) for 1.381 0.992-1.922) 76%) highlighted variability. Sensitivity analyses publication evident. is potential factor demonstrating an elevated likelihood developing Future research required investigate underlying mechanisms confounding factors that may influence this association.

Language: Английский

Atrial High-Rate Episodes in Elderly Patients: The Anticoagulation Therapy Dilemma

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(12), P. 3566 - 3566

Published: June 18, 2024

Atrial fibrillation (AF) has been associated with higher morbidity and mortality rates, especially in older patients. Subclinical atrial (SCAF) is defined as the presence of high-rate episodes (AHREs) > 190 bpm for 10 consecutive beats 6 min <24 h, detected by cardiac implanted electronic devices (CIEDs). The selection eligible patients anticoagulation therapy among elderly individuals AHREs through CIEDs remains a contentious issue. meta-analysis ARTESiA NOAH-AFNET clinical trials revealed that taking Edoxaban or Apixaban oral can reduce risk stroke approximately 32% while increasing major bleeding 62%. However, it still unclear which are, SCAF, those who take highest net benefit from anticoagulant therapy. present review summarizes current evidence on this intriguing issue suggests strategies to try better stratify systemic embolism AHREs. We propose incorporating some parameters including chronic kidney disease (CKD), obesity, enlarged left volume, efficacy blood pressure management, frailty into traditional CHA2DS2-VASc score. Future will be needed verify usefulness proposed prognostic score mainly view personalized therapeutic approach SCAF.

Language: Английский